Evidence map›Paper›PMID 25287928›Full record

ArticleInfection and immunity2014

Gene deletions in Mycobacterium bovis BCG stimulate increased CD8+ T cell responses.

Michael W Panas, Jaimie D Sixsmith, KeriAnn White, Birgit Korioth-Schmitz, Shana T Shields, Brian T Moy, Sunhee Lee, Joern E Schmitz, William R Jacobs, Steven A Porcelli and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in Infection and immunity, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Interleukin-17A as a Biomarker for Bovine Tuberculosis.Clinical and vaccine immunology : CVI · 2016
    Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Michael W PanasCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts USA.
Jaimie D SixsmithCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts USA.
KeriAnn WhiteCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts USA.
Birgit Korioth-SchmitzCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts USA.
Shana T ShieldsCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts USA.
Brian T MoyCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts USA.
Sunhee LeeHuman Vaccine Institute and Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA.
Joern E SchmitzCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts USA.
William R JacobsHoward Hughes Medical Institute, Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, USA.
Steven A PorcelliHoward Hughes Medical Institute, Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, USA.
Barton F HaynesHuman Vaccine Institute and Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA.
Norman L LetvinCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts USA.
Geoffrey O GillardCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts USA geoff.gillard1@gmail.com.
Beth Israel Deaconess Medical Center · USDuke Medical Center · USHoward Hughes Medical Institute · US

Funding

The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI ROBERT A. PARKER · 2004 to 2026
$94.4M
Immunology/Pathology CoreP30AI051519 · NIAID · YESHIVA UNIVERSITY · PI GOLDSTEIN, HARRIS · 2003 to 2013
$18.6M
"The Tuberculous Granuloma"P01AI063537 · NIAID · ALBERT EINSTEIN COL OF MED YESHIVA UNIV · PI CHAN, JOHN R. · 2005 to 2015
$15.7M
Molecular Genetic Analysis of Mycobacterium TuberculosisR37AI026170 · NIAID · ALBERT EINSTEIN COL OF MED YESHIVA UNIV · PI WILLIAM Robert JACOBS · 2004 to 2026
$7.7M
MOLECULAR GENETIC ANALYSIS OF MYCOBACTERIUM TUBERCULOSISR01AI026170 · NIAID · YESHIVA UNIVERSITY · PI JACOBS, WILLIAM ROBERT · 1989 to 2022
$7.1M
CD1d/NKT-binding glycolipids in enhancing the immunogenicity of a malaria vaccineR01AI070258 · NIAID · AARON DIAMOND AIDS RESEARCH CENTER · PI TSUJI, MORIYA · 2012 to 2016
$2.2M
Construction of safe and effective live tuberculosis vaccinesR01AI093649 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI PORCELLI, STEVEN A · 2011 to 2015
$2.1M
MOLECULAR GENETIC ANALYSIS OF MYCOBACTERIUM TUBERCULOSISR22AI026170 · NIAID · YESHIVA UNIVERSITY · PI JACOBS, WILLIAM ROBERT · 1989 to 1991
–
Howard Hughes Medical InstituteNIAID NIH HHS AI-051519NIAID NIH HHS AI26170NIAID NIH HHS P01 AI063537NIAID NIH HHS P30 AI051519NIAID NIH HHS P30 AI060354NIAID NIH HHS P30AI060354NIAID NIH HHS R01 AI026170NIAID NIH HHS R01 AI070258NIAID NIH HHS R01 AI093649NIAID NIH HHS R37 AI026170
6 · The paper itself

Abstract

Mycobacteria, the etiological agents of tuberculosis and leprosy, have coevolved with mammals for millions of years and have numerous ways of suppressing their host's immune response. It has been suggested that mycobacteria may contain genes that reduce the host's ability to elicit CD8(+) T cell responses. We screened 3,290 mutant Mycobacterium bovis bacillus Calmette Guerin (BCG) strains to identify genes that decrease major histocompatibility complex (MHC) class I presentation of mycobacterium-encoded epitope peptides. Through our analysis, we identified 16 mutant BCG strains that generated increased transgene product-specific CD8(+) T cell responses. The genes disrupted in these mutant strains had disparate predicted functions. Reconstruction of strains via targeted deletion of genes identified in the screen recapitulated the enhanced immunogenicity phenotype of the original mutant strains. When we introduced the simian immunodeficiency virus (SIV) gag gene into several of these novel BCG strains, we observed enhanced SIV Gag-specific CD8(+) T cell responses in vivo. This study demonstrates that mycobacteria carry numerous genes that act to dampen CD8(+) T cell responses and suggests that genetic modification of these genes may generate a novel group of recombinant BCG strains capable of serving as more effective and immunogenic vaccine vectors.

Indexed as

Gene DeletionAIDS VaccinesAnimalsCD8-Positive T-Lymphocytesgag Gene Products, Human Immunodeficiency VirusImmune ToleranceMice, Inbred C57BLMycobacterium bovisAIDS Vaccinesgag Gene Products, Human Immunodeficiency Virus

Identifiers

PMID25287928
PMCPMC4249275
OpenAlexW2157197382

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.